Microbiota Transplant Therapy Is Safe and Feasible in Pulmonary Arterial Hypertension

IF 8.4 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

JACC: Basic to Translational Science Pub Date : 2025-08-12 DOI:10.1016/j.jacbts.2025.101347

Daphne Moutsoglou MD, PhD , Madelyn Blake BS , Dina C. Belhasan MD , Gretchen Peichel BAN , Brenda M. Vang AAS , E. Kenneth Weir MD , Sharon Lopez BS , Kurt W. Prins MD, PhD , Amanda J. Kabage MS , Sasha Z. Prisco MD, PhD , Benjamin P. Kremer BS , Alexander Khoruts MD, MS , Thenappan Thenappan MD

{"title":"Microbiota Transplant Therapy Is Safe and Feasible in Pulmonary Arterial Hypertension","authors":"Daphne Moutsoglou MD, PhD , Madelyn Blake BS , Dina C. Belhasan MD , Gretchen Peichel BAN , Brenda M. Vang AAS , E. Kenneth Weir MD , Sharon Lopez BS , Kurt W. Prins MD, PhD , Amanda J. Kabage MS , Sasha Z. Prisco MD, PhD , Benjamin P. Kremer BS , Alexander Khoruts MD, MS , Thenappan Thenappan MD","doi":"10.1016/j.jacbts.2025.101347","DOIUrl":null,"url":null,"abstract":"<div><div>Pulmonary arterial hypertension (PAH) is a complex inflammatory disease that the gut microbiome likely contributes to and may be a potential therapeutic avenue for nontoxically improving outcomes. Here, we show that microbiota transplant therapy (MTT) is safe and feasible. The MTT regimen achieves only modest levels of donor microbiota engraftment but is accompanied by a transient reduction in circulating pro-inflammatory cytokines. These findings of decreased systemic inflammation with only modest donor engraftment support the potential of MTT as a novel treatment for PAH. (Microbiota Transplant Therapy for Pulmonary Arterial Hypertension: Early Safety and Feasibility Study; <span><span>NCT04884971</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14831,"journal":{"name":"JACC: Basic to Translational Science","volume":"10 9","pages":"Article 101347"},"PeriodicalIF":8.4000,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC: Basic to Translational Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452302X25003006","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Pulmonary arterial hypertension (PAH) is a complex inflammatory disease that the gut microbiome likely contributes to and may be a potential therapeutic avenue for nontoxically improving outcomes. Here, we show that microbiota transplant therapy (MTT) is safe and feasible. The MTT regimen achieves only modest levels of donor microbiota engraftment but is accompanied by a transient reduction in circulating pro-inflammatory cytokines. These findings of decreased systemic inflammation with only modest donor engraftment support the potential of MTT as a novel treatment for PAH. (Microbiota Transplant Therapy for Pulmonary Arterial Hypertension: Early Safety and Feasibility Study; NCT04884971)

查看原文本刊更多论文

微生物群移植治疗肺动脉高压安全可行

肺动脉高压（PAH）是一种复杂的炎症性疾病，肠道微生物群可能是一种无毒改善结果的潜在治疗途径。在这里，我们证明微生物群移植治疗（MTT）是安全可行的。MTT方案仅达到适度的供体微生物群植入水平，但伴随着循环促炎细胞因子的短暂减少。这些发现减少了全身性炎症，只有适度的供体植入支持MTT作为PAH的新治疗方法的潜力。微生物群移植治疗肺动脉高压：早期安全性和可行性研究NCT04884971)

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JACC: Basic to Translational Science CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

14.20

自引率

1.00%

发文量

161

审稿时长

16 weeks

期刊介绍： JACC: Basic to Translational Science is an open access journal that is part of the renowned Journal of the American College of Cardiology (JACC). It focuses on advancing the field of Translational Cardiovascular Medicine and aims to accelerate the translation of new scientific discoveries into therapies that improve outcomes for patients with or at risk for Cardiovascular Disease. The journal covers thematic areas such as pre-clinical research, clinical trials, personalized medicine, novel drugs, devices, and biologics, proteomics, genomics, and metabolomics, as well as early phase clinical trial methodology.